OECI-EACR precision medicine for cancer: Conference report 1–4 March 2015, Luxembourg

The ‘Precision Medicine for Cancer’ was the first meeting of a new series of conferences organised biannually by the European Association for Cancer Research (EACR) and the Organisation for European Cancer Institutes (OECI). The main objective of the meeting was to focus on novel topics in precision medicine by allowing strong interactions between participants and to access the speakers easily. As the first implementations of personalised medicine are appreciated in the clinic, the aim of the meeting was to further educate both researchers and clinicians and learn more from the novel approaches in the field. Similarly, the interaction between two organisations—the research-oriented EACR and the clinic-oriented OECI—was of a great value for the meeting. This OECI-EACR 2015 report will highlight the major findings of this outstanding meeting.

[1]  T. Jacks,et al.  The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  N. Carragher,et al.  Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma , 2015, Cancer cell.

[3]  A. Harris,et al.  Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress , 2015, Cancer cell.

[4]  J. Toppari,et al.  CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance , 2014, Oncotarget.

[5]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[6]  Ton N Schumacher,et al.  Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition. , 2014, Cell reports.

[7]  S. Pfister,et al.  Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy , 2014, Clinical Cancer Research.

[8]  A. Bardelli,et al.  Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.

[9]  M. Esteller,et al.  A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition. , 2014, Cancer research.

[10]  P. Lønning,et al.  The multitude of molecular analyses in cancer: the opening of Pandora’s box , 2014, Genome Biology.

[11]  R. Marais,et al.  No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients , 2014, Molecular oncology.

[12]  M. Dunning,et al.  Genome-driven integrated classification of breast cancer validated in over 7,500 samples , 2014, Genome Biology.

[13]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[14]  David T. W. Jones,et al.  Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing , 2014, Nature.

[15]  A. Frigessi,et al.  Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.

[16]  Samra Turajlic,et al.  BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.

[17]  A. Bardelli,et al.  Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.

[18]  Mathew J Garnett,et al.  The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response? , 2014, Current opinion in genetics & development.

[19]  R. Sandberg,et al.  RNA helicase A is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma. , 2014, Cancer discovery.

[20]  G. Berchem,et al.  Autophagic degradation of GZMB/granzyme B , 2014, Autophagy.

[21]  Jason A. Grundstad,et al.  Next-Generation Sequencing of Disseminated Tumor Cells , 2013, Front. Oncol..

[22]  J. Westermarck,et al.  Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. , 2013, Cancer research.

[23]  E. Lenkiewicz,et al.  Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes , 2013, Acta Neuropathologica.

[24]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[25]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[26]  G. Berchem,et al.  Stromal cell-induced miRNA alteration in chronic lymphocytic leukemia: how a minute and unavoidable cell contamination impairs miRNA profiling , 2013, Leukemia.

[27]  Carlos Caldas,et al.  A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.

[28]  E. Schröck,et al.  Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells , 2013, Brain : a journal of neurology.

[29]  G. Millington.  Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949–54) , 2013, Clinical and experimental dermatology.

[30]  M. Esteller,et al.  Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.

[31]  M. Gore,et al.  Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.

[32]  M. Esteller,et al.  BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer , 2012, Epigenetics.

[33]  Gerald C. Chu,et al.  Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma , 2012, Nature Medicine.

[34]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[35]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[36]  P. Romero,et al.  Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. , 2011, Cancer research.

[37]  David J. Galas,et al.  MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia , 2011, Proceedings of the National Academy of Sciences.

[38]  S. Niclou,et al.  Critical appraisal of the side population assay in stem cell and cancer stem cell research. , 2011, Cell stem cell.

[39]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[40]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[41]  A. McCullough.  RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .